Last reviewed · How we verify
Prevention of atherothrombotic events at high risk of ischaemic events
Approved treatments
- Xarelto · University Hospital, Montpellier
- Xarelto · Johnson & Johnson
Selective FXa inhibitor that decreases thrombin generation without requiring cofactors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of atherothrombotic events at high risk of ischaemic events patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of atherothrombotic events at high risk of ischaemic events treatment landscape brief
- Prevention of atherothrombotic events at high risk of ischaemic events treatment updates RSS
Frequently asked questions about Prevention of atherothrombotic events at high risk of ischaemic events
What drugs treat Prevention of atherothrombotic events at high risk of ischaemic events?
Tracked treatments include Xarelto.
What is the treatment for Prevention of atherothrombotic events at high risk of ischaemic events?
Standard treatment for Prevention of atherothrombotic events at high risk of ischaemic events includes Xarelto. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of atherothrombotic events at high risk of ischaemic events patent cliff · Prevention of atherothrombotic events at high risk of ischaemic events CI report
- Treatment: Xarelto · University Hospital, Montpellier
- Treatment: Xarelto · Johnson & Johnson
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing